ATYR
Price
$3.29
Change
+$0.01 (+0.30%)
Updated
May 12, 01:40 PM (EDT)
Capitalization
291.46M
93 days until earnings call
NTLA
Price
$8.80
Change
+$0.68 (+8.37%)
Updated
May 12, 02:11 PM (EDT)
Capitalization
841.1M
80 days until earnings call
Ad is loading...

ATYR vs NTLA

Header iconATYR vs NTLA Comparison
Open Charts ATYR vs NTLABanner chart's image
aTyr Pharma
Price$3.29
Change+$0.01 (+0.30%)
Volume$1.1K
Capitalization291.46M
Intellia Therapeutics
Price$8.80
Change+$0.68 (+8.37%)
Volume$150
Capitalization841.1M
ATYR vs NTLA Comparison Chart
Loading...
ATYR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATYR vs. NTLA commentary
May 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATYR is a Hold and NTLA is a Buy.

Ad is loading...
COMPARISON
Comparison
May 12, 2025
Stock price -- (ATYR: $3.28 vs. NTLA: $8.12)
Brand notoriety: ATYR and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATYR: 66% vs. NTLA: 149%
Market capitalization -- ATYR: $291.46M vs. NTLA: $841.1M
ATYR [@Biotechnology] is valued at $291.46M. NTLA’s [@Biotechnology] market capitalization is $841.1M. The market cap for tickers in the [@Biotechnology] industry ranges from $296.96B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATYR’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • ATYR’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, NTLA is a better buy in the long-term than ATYR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATYR’s TA Score shows that 6 TA indicator(s) are bullish while NTLA’s TA Score has 5 bullish TA indicator(s).

  • ATYR’s TA Score: 6 bullish, 4 bearish.
  • NTLA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ATYR is a better buy in the short-term than NTLA.

Price Growth

ATYR (@Biotechnology) experienced а -8.89% price change this week, while NTLA (@Biotechnology) price change was -8.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.37%. For the same industry, the average monthly price growth was +12.65%, and the average quarterly price growth was -9.55%.

Reported Earning Dates

ATYR is expected to report earnings on Aug 13, 2025.

NTLA is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (-1.37% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($841M) has a higher market cap than ATYR($291M). ATYR YTD gains are higher at: -9.392 vs. NTLA (-30.360). ATYR has higher annual earnings (EBITDA): -66.37M vs. NTLA (-523.98M). NTLA has more cash in the bank: 602M vs. ATYR (72.1M). ATYR has less debt than NTLA: ATYR (13.3M) vs NTLA (210M). NTLA has higher revenues than ATYR: NTLA (57.9M) vs ATYR (235K).
ATYRNTLAATYR / NTLA
Capitalization291M841M35%
EBITDA-66.37M-523.98M13%
Gain YTD-9.392-30.36031%
P/E RatioN/AN/A-
Revenue235K57.9M0%
Total Cash72.1M602M12%
Total Debt13.3M210M6%
FUNDAMENTALS RATINGS
ATYR vs NTLA: Fundamental Ratings
ATYR
NTLA
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
28
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
4264
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5095

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (28) in the Biotechnology industry is somewhat better than the same rating for ATYR (83) in the null industry. This means that NTLA’s stock grew somewhat faster than ATYR’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ATYR (100) in the null industry. This means that NTLA’s stock grew similarly to ATYR’s over the last 12 months.

NTLA's SMR Rating (97) in the Biotechnology industry is in the same range as ATYR (100) in the null industry. This means that NTLA’s stock grew similarly to ATYR’s over the last 12 months.

ATYR's Price Growth Rating (42) in the null industry is in the same range as NTLA (64) in the Biotechnology industry. This means that ATYR’s stock grew similarly to NTLA’s over the last 12 months.

ATYR's P/E Growth Rating (100) in the null industry is in the same range as NTLA (100) in the Biotechnology industry. This means that ATYR’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATYRNTLA
RSI
ODDS (%)
Bullish Trend 5 days ago
70%
Bullish Trend 4 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
81%
Momentum
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
85%
MACD
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
78%
Advances
ODDS (%)
Bullish Trend 13 days ago
79%
Bullish Trend 5 days ago
77%
Declines
ODDS (%)
Bearish Trend 6 days ago
84%
Bearish Trend 7 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
89%
Aroon
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 4 days ago
87%
View a ticker or compare two or three
Ad is loading...
ATYR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA298.2613.44
+4.72%
Tesla
GME27.540.76
+2.84%
GameStop Corp
AAPL198.531.04
+0.53%
Apple
SPY564.34-0.72
-0.13%
SPDR® S&P 500® ETF
BTC.X104106.360000-589.968750
-0.56%
Bitcoin cryptocurrency

ATYR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATYR has been loosely correlated with MGTX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ATYR jumps, then MGTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATYR
1D Price
Change %
ATYR100%
-1.80%
MGTX - ATYR
46%
Loosely correlated
-0.91%
NTLA - ATYR
40%
Loosely correlated
-1.93%
CRNX - ATYR
38%
Loosely correlated
-6.18%
ERAS - ATYR
38%
Loosely correlated
N/A
SLDB - ATYR
37%
Loosely correlated
-0.36%
More

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with CRSP. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-1.93%
CRSP - NTLA
68%
Closely correlated
-1.44%
BEAM - NTLA
65%
Loosely correlated
+0.93%
RXRX - NTLA
60%
Loosely correlated
-1.37%
RCKT - NTLA
59%
Loosely correlated
-0.71%
ALLO - NTLA
58%
Loosely correlated
-1.69%
More